Search
Solid Biosciences Inc
SLDBAdd to Watchlist
9.250USD
+0.460+5.23%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
910.66MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-24The current earnings forecast score of Solid Biosciences Inc is 8.86, ranking 42 out of 388 in the Biotechnology & Medical Research industry. The average price target is 15.00, with a high of 20.00 and a low of 9.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
18.500
Target Price
+122.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Solid Biosciences Inc
SLDB
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Solid Biosciences Inc's price target?
Analysts forecast that Solid Biosciences Inc's price target is USD 15.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 9.00.
How have Solid Biosciences IncSLDB's recent earnings per share performed?
The market expectation was USD -0.52, while Solid Biosciences IncSLDB's earnings per share (EPS) for the previous quarter was USD -0.53. EPS for the next quarter is expected at USD -0.47.
What is the analyst rating for Solid Biosciences Inc?
Based on the ratings of Solid Biosciences Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
